Isis Pharmaceuticals and Johnson & Johnson’s Janssen subsidiary have inked a $35 million agreement in which the two will use Isis’s RNA therapy platform to develop treatments for gastrointestinal autoimmune disorders.
The $35 million payment covers three programs and later milestones could garner Isis an additional $800 million. RNA treatments are called “antisense” and are being pursued across a variety of conditions, including cancers and genetic disorders.
